0001157523-17-000533.txt : 20170216 0001157523-17-000533.hdr.sgml : 20170216 20170216170040 ACCESSION NUMBER: 0001157523-17-000533 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20170216 FILED AS OF DATE: 20170216 DATE AS OF CHANGE: 20170216 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Aurinia Pharmaceuticals Inc. CENTRAL INDEX KEY: 0001600620 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36421 FILM NUMBER: 17618615 BUSINESS ADDRESS: STREET 1: #1203-4464 MARKHAM STREET CITY: VICTORIA BC STATE: A1 ZIP: V8Z 7X8 BUSINESS PHONE: 250-708-4272 MAIL ADDRESS: STREET 1: #1203-4464 MARKHAM STREET CITY: VICTORIA BC STATE: A1 ZIP: V8Z 7X8 6-K 1 a51511678.htm AURINIA PHARMACEUTICALS INC. 6-K
 

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 

 
FORM 6-K
 


 
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE
SECURITIES EXCHANGE ACT OF 1934

 
Dated February 16, 2017
 
Commission File Number 001-36421

 

AURINIA PHARMACEUTICALS INC.
(Exact name of Registrant as specified in its charter)

 
N/A
(Translation of Registrant’s Name)

 
#1203-4464 Markham Street
Victoria, British Columbia
V8Z7X8
(250) 708-4272
(Address and telephone number of registrant’s principal executive offices)

 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 
Form 20-F  ☐            Form 40-F  ☒

 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b) (1):  ☐
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b) (7):  ☐
 
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

 
Yes  ☒             No  ☐

 
This Form 6-K is hereby filed and incorporated by reference into the Registrant’s Registration Statement on Form F-10 (File No. 333-206994).
 
 

 
SIGNATURES

 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 
Dated: February 16, 2017.
 
 
 
  Aurinia Pharmaceuticals Inc.  
       
 
By:
/s/ Dennis Bourgeault  
    Name: Dennis Bourgeault  
   
Title:   Chief Financial Officer
  
       
 
 
2


 
EXHIBIT INDEX
 
 
 
     
 
Exhibit
  
 
Description of Exhibit
   
99.1
  
Material Change Report dated February 16, 2017

 
Exhibit 99.1 included with this report on Form 6-K is hereby incorporated by reference as an exhibit to the Registrant’s Registration Statement on Form F-10 (File No. 333-206994), as amended or supplemented.
 

3
 
 EX-99.1 2 a51511678exhibit99_1.htm EXHIBIT 99.1
Exhibit 99.1
 
FORM 51-102F3
 
MATERIAL CHANGE REPORT
 
 
ITEM 1.
 
 Name and Address of Company
 
 
 
 
 
Aurinia Pharmaceuticals Inc. (the “Company”)
 
 
1203 – 4464 Markham Street
 
 
Victoria, BC V8Z 7X8
 
 
 
ITEM 2. 
 
Date of Material Change
 
 
 
 
 
 February 6, 2017
 
 
 
ITEM 3.
 
 News Release
 
 
 
 
 
 A news release relating to the material change described herein was disseminated on February 6, 2017 via Business Wire.
 
 
 
ITEM 4. 
 
Summary of Material Change
 
 
 
 
 
 The Company announced the resignation of Charles Rowland as Chief Executive Officer and director of the Company and the appointment of Dr. Richard M. Glickman, the Company's founder and Chairman of the Board, as the Company’s Chairman and Chief Executive Officer, effective February 6, 2017.
 
 
 
ITEM 5.
 
 Full Description of Material Change
 
 
 
 
 
The Company announced the resignation of Charles Rowland as Chief Executive Officer and director of the Company and the appointment of Dr. Richard M. Glickman, the Company's founder and Chairman of the Board, as the Company’s Chairman and Chief Executive Officer, effective February 6, 2017.
 
 
 
ITEM 5.2.
 
Disclosure of Restructuring Transactions
 
 
 
 
 
 Not applicable.
 
 
 
ITEM 6.
 
Reliance on Subsection 7.1(2) of National Instrument 51-102
 
 
 
 
 
Not applicable.
 
 
 
ITEM 7.
 
 Omitted Information
 
 
 
 
 
There are no significant facts required to be disclosed herein which have been omitted.
 
 
 
ITEM 8. 
 
 Executive Officer
 
 
 
 
 
For further information, please contact:
 
 
 
 
 
Michael R. Martin, Chief Operating Officer
 
 
 250-415-9713
 
 
mmartin@auriniapharma.com
 
 
 
ITEM 9. 
 
Date of Report
 
 
 
 
 
 February 16, 2017